Company: ARWR
Filing Date: 2025-10-10
Form Type: 10-K/A
Source: 0000879407-25-000013
Chunk: 41

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-10-10
Form: 10-K/A
Chunk 41
---
        |     | Value Realized on 
 Vesting (2)       |           |           |
|:---------------------|:----|:------------------------------------|:----|-------:|:----|:--|:------------------|----------:|:--|:----|:--|:-----------------|:----|-------:|:----|:------------------|----------:|----------:|
| Christopher Anzalone |     |                                     |     | 57,499 |     |   | $                 | 1,024,000 |   |     |   |                  |     | 95,087 |     | $                 | 2,603,325 |           |
| Kenneth Myszkowski   |     |                                     |     |      — |     |   |                   |           | — |     |   |                  |     | 66,250 |     | $                 | 2,212,813 |           |
| Patrick O’Brien      |     |                                     |     |      — |     |   |                   |           | — |     |   |                  |     | 63,750 |     | $                 | 2,139,688 |           |
| James Hamilton       |     |                                     |     |      — |     |   |                   |           | — |     |   |                  |     | 52,500 |     | $                 | 1,773,225 |           |
| Javier San Martin    |     |                                     |     |      — |     | — |                   |           | — |     | — |                  |     | 52,500 |     |                   |           | 1,570,200 |
| Tracie Oliver        |     |                                     |     |      — |     |   |                   |           | — |     |   |                  |     | 17,625 |     | $                 |   460,191 |           |

(1) Value is calculated as the price of our Common Stock upon exercise, less the exercise price, multiplied by the number of shares exercised.

(2) Value is calculated as the price of our Common Stock upon vesting, multiplied by the number of shares vested.

Termination Benefits - Potential Payments Upon Termination or Change in Control

The Company has the following severance or change of control arrangements with its NEOs:

Dr. Anzalone’s employment agreement with the Company provides that, if the Company terminates Dr. Anzalone’s employment